The European Commission has launched a public consultation to gather views on the strengths and weaknesses of the European Medicines Agency’s system for collecting fees from the pharmaceutical industry for regulatory services and remunerating the regulators that perform those services.
Aimed at all relevant stakeholders, but particularly those with active experience of the fee system, such as the pharmaceutical industry,...








